MarketBeat
25 Oct 2026, 16:03 UTC · 2h ago
Impact · against what's priced in
ODTX is facing a significant valuation vacuum until H2 2027, as the market now has a concrete timeline for the lead asset's next binary catalysts. While the Phase IIa data is encouraging and cash runway is secure, the 20-month wait for induction readouts limits near-term upside.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 2 new · 2 priced in
Odyssey expects induction readouts for its Phase IIb monotherapy and Phase IIa combination studies of OD-001 in the second half of 2027.
Newwebcast on 2026-10-25
So whatThis establishes a ~20-month wait for the next binary catalyst for the lead asset.
More positive than 93% of claims this week
The OD-001 Phase IIa trial showed a 27% clinical-remission rate and a mean 2.4-point reduction in modified Mayo score at the 20 mg twice-daily dose.
Continue reading
5 related stories
The establishment of H2 2027 as the readout window for Phase IIb monotherapy and Phase IIa combination studies creates a long horizon for the next major catalyst. Positive proof-of-concept data (27% clinical remission at 20mg BID) and a cash runway into H2 2028 provide a stable floor, while the planned OD-002 dosing in H1 2027 offers pipeline diversification.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inCEO stated company had previously reported 27% remission
So whatThe 60%+ clinical response rate provides a baseline for the upcoming placebo-controlled Phase IIb study.
More positive than 78% of claims this week
Odyssey holds $433 million in cash as of June 30 and expects this to fund operations into the second half of 2028.
Priced indata as of June 30
So whatCurrent liquidity covers the gap until the H2 2027 readouts without requiring immediate dilutive financing.
More positive than 64% of claims this week
The company plans to file a clinical trial application for OD-002 this year and begin dosing healthy participants in the first half of 2027.
Newwebcast on 2026-10-25
So whatThis diversifies the pipeline risk beyond the RIPK2 program by Q1/Q2 2027.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Positive Phase IIa data for OD-001 showing clinical remission and a favorable safety profile, along with strong cash runway.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
—
ODTX hasn't traded since this ran. Last close $19.60 (Oct 23); the reaction starts at the next open.
ODTX chart →
